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Mucosal leishmaniasis: A forgotten disease, description 
and identification of species in 50 Colombian cases
Sandra Muvdi-Arenas, Clemencia Ovalle-Bracho
Centro Dermatológico Federico Lleras Acosta, Bogotá, D.C., Colombia 
Introduction: Mucosal leishmaniasis has a progressive course and can cause deformity 
and even mutilation in the affected areas. It is endemic in the American continent and it is 
mainly caused by Leishmania (Viannia) braziliensis.
Objective: To describe a series of mucosal leishmaniasis cases and the infectious 
Leishmania species.
Materials and methods: We included 50 patients with a clinical diagnosis of mucosal 
leishmaniasis and parasitological confirmation, and we described their clinical and 
laboratory results. We performed species typing by PCR-RFLP using the miniexon 
sequence and hsp70 genes; confirmation was done by sequencing.
Results: The median time of disease evolution was 2.9 years (range: 1 month to 16 years). 
The relevant clinical findings included mucosal infiltration (94%), cutaneous leishmaniasis 
scar (74%), total loss of the nasal septum (24%), nasal deformity (22%), and mucosal 
ulceration (38%). The symptoms reported included nasal obstruction (90%), epistaxis 
(72%), rhinorrhea (72%), dysphonia (28%), dysphagia (18%), and nasal pruritus (34%). 
The histopathological study revealed a pattern compatible with leishmaniasis in 86% of the 
biopsies, and amastigotes were identified in 14% of them. The Montenegro skin test was 
positive in 86% of patients, immunofluorescence in 84%, and culture in 8%. Leishmania 
(V.) braziliensis was identified in 88% of the samples, L. (V) panamensis in 8%, and L. (V.) 
guyanensis and L. (L.) amazonensis in 2% respectively.
Conclusion: In this study, we found a severe nasal disease with destruction and deformity of 
the nasal septum in 25% of the cases, probably associated with late diagnosis. Leishmania (V.) 
braziliensis was the predominant species. We described a case of mucosal leishmaniasis in 
Colombia caused by L. (L.) amazonensis for the first time.
Keywords: Leishmania; leishmaniasis, mucocutaneous; molecular typing; polymerase 
chain reaction.
Leishmaniasis mucosa: una enfermedad olvidada, descripción e identificación de 
especies en 50 casos colombianos 
Introducción. La leishmaniasis mucosa tiene un curso progresivo y puede causar 
deformidad e incluso mutilación de las zonas afectadas. Es endémica en el continente 
americano y es causada principalmente por Leishmania (Viannia) brasiliensis. 
Objetivo. Describir una serie de casos de leishmaniasis mucosa y las especies de 
Leishmania infecciosas.
Materiales y métodos. Se estudiaron 50 pacientes con diagnóstico clínico de 
leishmaniasis mucosa y confirmación parasitológica. Se describieron sus características 
clínicas y los resultados de laboratorio. La tipificación de especies se hizo mediante 
reacción en cadena de la polimerasa de los polimorfismos de la longitud de los fragmentos 
de restricción (Restriction Fragment Length Polymorphism Polymerase Chain Reaction, 
PCR-RFLP) en la secuencia del miniexon y el gen hsp70 y se confirmó por secuenciación.
Resultados. La evolución de la enfermedad fue de un mes a dieciséis años (mediana de 
2,8 años). Los hallazgos clínicos fueron los siguientes: infiltración mucosa (94 %), cicatriz 
de leishmaniasis cutánea (74 %), pérdida total del tabique nasal (24 %), deformidad nasal 
(22 %) y ulceración (38 %). Los síntomas reportados fueron: obstrucción nasal (90 %), 
epistaxis (72 %), rinorrea (72 %), disfonía (28 %), disfagia (18 %) y prurito nasal (34 %). 
La histopatología mostró un patrón compatible con leishmaniasis en 86 % de las biopsias 
y se identificaron amastigotes en 14 % de ellas. La prueba de Montenegro fue positiva en 
86 % de los pacientes, la inmunofluorescencia en 84 %, y el cultivo en 8 %. Leishmania 
(V.) brasiliensis se identificó en 88 % de las muestras, L. (V) panamensis en 8 %, y L. (V.) 
guyanensis y L. (L.) amazonensis en 2 %, respectivamente.
Conclusión. Se encontró enfermedad nasal grave con destrucción y deformidad del 
tabique nasal en una cuarta parte de los casos, probablemente debido a un diagnóstico 
tardío. Leishmania (V.) brasiliensis fue la especie predominante. Se describe por primera 
vez un caso de leishmaniasis mucosa causado por L. (L.) amazonensis en Colombia.
Palabras clave: Leishmania; leishmaniasis mucocutánea; tipificación molecular; reacción 
en cadena de la polimerasa. 
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Mucosal leishmaniasis occurs mainly in the Americas affecting mostly 
the nasal mucosa. It has a progressive course and can cause destruction, 
deformity, and mutilation in severe cases (1,2). Mucosal leishmaniasis is 
caused by Leishmania species of the subgenus Viannia. Most of the cases 
reported in the literature are associated with L. (V.) braziliensis followed by L. 
(V.) panamensis and L. (V.) guyanensis (3). 
This is a rare disease and the scientific literature is scarce on the topic. It 
is often underdiagnosed or confused with other diseases. In addition, most 
of the case series reported are small and they lack information on clinical 
findings, confirmatory laboratory tests, and species typing (4,5). In the 
literature reviewed for the present study, we found only one study in Colombia 
collecting clinical information on this form of the disease (6).
We describe here a series of 50 cases of mucosal leishmaniasis treated at 
the Centro Dermatológico Federico Lleras Acosta in Bogotá, D.C., Colombia, 
focusing on their clinical characteristics, diagnostic tests, and the Leishmania 
species identified by polymerase chain reaction-restriction fragment length 
polymorphism (PCR-RFLP) using the miniexon sequence and the hsp70 gene.
Materials and methods
Study population 
We studied 50 patients from the Centro Dermatológico Federico 
Lleras Acosta’s leishmanisis registers who were diagnosed with mucosal 
leishmaniasis and had tested positive for the miniexon gene by PCR. 
Leishmania parasites were isolated in four patients. 
The data collected included the time of disease evolution, a history of 
having been in an endemic area, and clinical signs and symptoms suggestive 
of the disease such as rhinorrhea, pruritus, nasal obstruction, epistaxis, 
ulcer, and perforation or destruction of the septum, dysphagia, dysphonia, 
and mucosal infiltration. Diagnostic tests included specific antibody titers 
measured by indirect immunofluorescence, Montenegro skin test, and 
histopathological study. 
Type of study
We conducted an observational descriptive study (case series).
Reference strains 
The following reference strains were included: L. (V.) braziliensis (MHOM/
BR/75/M2903), L. (V.) panamensis (MHOM/PA/71/LS94), L. (V.) guyanensis 
(MHOM/BR/75/M4147), L. (L.) amazonensis (IFLA/BR/67/PH8), and L. (L.) 
mexicana (MNCY/BZ/62/M379). We used the electrophoretic and restriction 
patterns of the reference strains to define the parasite species.
DNA extraction
DNA extraction of both the reference strains and the fresh biopsies was 
performed using the DNeasy Blood and Tissue Kit™ (Qiagen, Maryland, USA) 
following the manufacturer’s instructions. The DNA was eluted in 100 µl of 
elution buffer solution and stored at -20°C until use. For the samples included 
in paraffin, DNA extraction was performed with Chelex-100™ (Bio-Rad, 
Hercules, USA) using a previously reported methodology (7). Finally, the DNA 
was rehydrated with 250 µl of distilled water and stored at -20°C until use.
60
Ovalle-Bracho C, Muvdi-Arenas S Biomédica 2019;39(Supl.2):58-65
Miniexon gene PCR 
The miniexon gene was amplified following the protocol reported by 
Marfurt, et al. in 2003 (8). Four microliters of DNA at a concentration of 10 ng/
µl were combined with 16 µl of a reaction mixture containing 1X amplification 
buffer (20 mM Tris-HCl (pH 8.4), 50 mM KCl; 2 mM MgCl2; 200 µM of each 
deoxynucleoside triphosphate; 0.5 µM of each primer (Fme 5´-TAT TGG TAT 
GCG AAA CTT CCG-3´ and Rme5´-ACA GAA ACT GAT ACT TAT ATA GCG-
3´); 0.05 U/µL Platinum Taq Polymerase™ (Invitrogen, São Paulo, Brazil), and 
6% DMSO in a final volume of 20 µl.
The amplification profile was as follows: 1 cycle of DNA denaturation at 95°C 
for 8 minutes; 40 amplification cycles of 95°C for 20 s, 55°C for 30 s, and 
72°C for 30 s, as well as one final extension cycle at 72°C for 5 minutes in 
the Mastercycler EP gradient S thermal cycler™ (Eppendorf AG, Hamburg, 
Germany). Each round of amplification contained a negative control, which 
had no DNA, and three positive controls from DNA of the reference strains of 
L. (V.) braziliensis, L. (L.) amazonensis, and L. (L.) mexicana. PCR products 
were visualized and digitized with the Gel Doc XR gel documentation 
system™ (Bio-Rad, California, USA).
Restriction fragment length polymorphism
The samples that showed an amplification profile of the miniexon gene 
compatible with the subgenus Viannia were subjected to restriction with the 
enzyme Hae III (Invitrogen, São Paulo, Brazil). The products were purified 
using the QIAquick PCR Purification Kit™ (Qiagen, Duesseldorf, Germany). 
For the restriction, we used 12.5 µl of the purified PCR product, 1.4 µl of 
reaction buffer, 0.5 µl of Hae III (10 u/µl) and then incubated at 37°C for 120 
min. We analyzed restriction products by 2.5% high-resolution agarose gel 
electrophoresis (Sigma-Aldrich, St. Louis, Missouri, USA) at 2.5 V/cm for 1.5 
hours using a 100-bp marker (Bioline, London, England).
We identified L. (V.) braziliensis in samples exhibiting digestion by the Hae 
III enzyme and a pattern of two bands close to 108 and 118 bp. The amplicons 
that did not present restriction fragments were identified as L. (V.) panamensis 
/ L. (V.) guyanensis. In these samples, the hsp70 gene was amplified 
following the protocol published by García, et al. in 2004. The reaction mixture 
contained 20 mM Tris-HCl, pH 8.4; 50 mM KCl; 2 mM MgCl2; 200 µM dATP, 
dCTP, dTTP, and dGTP; 0.4 µM HSP70 for 5’-GAC GGT GCC TGC CTA 
CTT CAA-3’ and HSP70 rev 5’-CCG CCC ATG CTC TGG TAC ATC-3’; 10% 
DMSO; 2 µl of DNA at a concentration of 10 ng/µl, and 0.05 U of Platinum Taq 
Polymerase™ (Invitrogen, São Paulo, Brazil) in a final volume of 50 µl.
The amplified product was purified and subjected to restriction with 10u/
µl BccI enzyme™ (New England Biolabs, Ipswich, England). The restriction 
products for the reference strains L. (V.) panamensis (MHOM/PA/71/LS94) 
and L. (V.) guyanensis (MHOM/BR/75/M4147) exhibited two bands of 428 
and 890 bp and three bands of approximately 346, 428, and 544 bp. The 
species in the biopsies were determined based on the restriction patterns 
obtained with the reference strains. 
Sequencing
The amplified fragments were sent for sequencing to confirm the species 
identified by PCR and PCR-RFLP. The BigDye Terminator, version 3.1, 
Cycle Sequencing Kit™ (Applied Biosystems, Foster City, USA) and the 
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3730xl DNA Analyzer™ (Applied Biosystems, Foster City, USA) were used. 
For the analysis, we used the Geneious Pro software, version 5.5.6, where 
alignments were made with the gene sequences of the species of interest 
available in NCBI.
Statistical analysis
We recorded PCR-RFLP-based miniexon and hsp70 gene typing and 
sequencing in a database. We calculated Cohen’s kappa coefficient with 
Stata™, version 13 (Stata Corp LP, College Station, Texas, USA) to determine 
the agreement between the two methodologies.
Ethical considerations
This study was approved by the Research Ethics Committee of the Centro 
Dermatológico Federico Lleras Acosta. The use of cryopreserved samples 
and the access to patient data were performed in accordance with the 
guidelines established by the committee, which are based on the Colombian 
regulations and the Declaration of Helsinki.
Results 
Seventy-six percent of the patients were men and 34% were women; their age 
range was 4-84 years with a median of 32 years. The time of disease evolution 
ranged from one month to 16 years with a median of 2.8 years. The patients 
came from 15 Colombian departments belonging to five geographical regions. 
One of the patients had oral mucosal involvement and the others had 
nasal mucosal lesions. A scar suggestive of cutaneous leishmaniasis was 
identified in 74% of cases and four cases had cutaneous leishmaniasis 
concomitant with mucosal lesions. The most frequent symptoms of nasal 
involvement included nasal obstruction (90%), rhinorrhea (72%), epistaxis 
(72%), and pruritus (34%). On the physical examination, infiltration of the 
affected mucosa was identified in 94% of the cases, septal perforation in 
58%, ulceration in 38%, and total loss of the nasal septum in 24% with an 
associated deformity in 22%. Additionally, 28% of the cases had dysphonia 
and 18% reported dysphagia. 
All cases were confirmed by miniexon gene PCR and the parasite 
was obtained by culture in four of 50 patients. A histopathological pattern 
compatible with leishmaniasis was observed in 86% of the biopsies and only 
in 14% of them, amastigotes were identified.
The Montenegro skin test was positive in 46 patients (86%). Specific 
indirect immunofluorescence was negative in 14% of the cases, titers were 
1/32 or 1/64 in 32% of them, and 1/128 or 1/512 in 54% was positive in 84% 
of the patients. 
Leishmania (V.) braziliensis was the predominant species, as it was 
identified in 88% of the cases, followed by L. (V.) panamensis (8%), L. (V.) 
guyanensis (2%), and L. (L.) amazonensis (2%). 
The patient in whom L. (L.) amazonensis was identified was a 62-year 
old farmer who lived in Caquetá, a department on the eastern region of 
the country. He had had cutaneous lesions for seven months and nasal 
symptoms for five months. On the physical exam, he showed disseminated 
papules, nodules, and infiltrated ulcerated plaques on face, trunk, and 
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extremities, some of which had lymphangitic involvement. On the nasal 
mucosa, he had erythema, infiltration, and ulceration. He was treated with 
pentavalent antimonials; his mucosal lesions responded well but had a 
cutaneous relapse. He was HIV negative. 
The agreement in species typing between the miniexon and hsp70 genes 
by PCR-RFLP was “very good” according to the Landis and Koch scale, and 
a kappa value of 1 was obtained.
Discussion
If the scale of mucosal leishmaniasis severity, proposed by Lessa and 
Lessa in 2012, is applied, 82% of our cases had severe mucosal disease: 
58% of them would be on stage IV of the disease with irreversible lesions 
(septal perforation), and 24% would be on stage V with deformities secondary 
to severe tissue destruction and total loss of the septum (2).
The characteristics of age, gender, and associated symptoms were similar 
to those described on the epidemiological reports of the Colombian Instituto 
Nacional de Salud (INS) for the last five years. In our study, we observed 
an increased frequency of previous scarring (74%) compared with the 
epidemiological reports of the INS (50%). 
In contrast, the frequency of septal perforation (58%) was considerably 
increased in our series compared with other reports, which ranged from 11% 
to 22% (2,6). 
The advanced stage of the disease is typically associated with late 
diagnosis, which was the case in our series (median time to diagnosis, 2.8 
years). The delay in the diagnosis could be explained by the following reasons: 
Lack of access to health services, the poor performance of diagnostic methods, 
and health professionals not familiarized with the disease, which leads to wrong 
diagnoses, inadequate management, and disease progression. 
In Brazil, Pereira Diniz, et al., described a series of 21 patients with a 
period until the diagnosis ranging from 5 months to 20 years with an average 
of 6 years (9). The duration of the disease is a factor that determines the 
spread of the parasites and is one of the main determining factors in the 
severity of mucosal lesions (9-11). Boaventura emphasizes that it is rare to 
access to clinically-diagnosed early stages of mucosal disease (12), which 
coincides with our findings. 
Mucosal lesions caused by Leishmania species of the subgenus Viannia 
are severe and progressive and can cause deformity and mutilation. Hence, a 
delay in diagnosis has aesthetic, functional, and emotional impact in patients 
(13). The majority of cases of mucosal leishmaniasis reported in the Americas 
are caused by L (V.) braziliensis followed by L. (V.) panamensis and L (V.) 
guyanensis. Previous studies have demonstrated that mucocutaneous 
leishmaniasis caused by L. (V.) panamensis is less destructive in most 
patients (6,14). In contrast, mucosal leishmaniasis caused by L. (V.) 
braziliensis presents more severe forms of the disease (1,14-16) and patients 
have increased frequency of septal perforation (17). 
In our series, almost 90% of the cases were caused by L. (V.) braziliensis, 
so we were unable to analyze differences in severity according to species. 
In one of our patients with nasal mucosal disease, we identified L. (L.) 
amazonensis as the infecting species. He had concomitant disseminated 
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cutaneous lesions and responded to pentavalent antimonials but relapsed. This 
is the first time that a case of mucosal leishmaniasis caused by this species has 
been described in Colombia; however, it has been reported in other countries (3).
The pathogenicity of mucosal leishmaniasis depends on several factors 
that involve the virulence of the parasite and the immune response of the 
host (2,16). In recent years, the presence of a virus of the Totiviridae family, 
Leishmania RNA virus (LRV1), has been described in some species of 
Leishmania, mainly L. (V.) braziliensis and L. (V.) guyanensis. This virus is 
capable of altering the immune response of the host via TLR 3 enhancing the 
inflammatory response and may be a determinant of disease severity (18).
The appearance of mucosal lesions in minors is rare. However, five (10%) 
of the cases in this series were under 18 years of age and two of these 
were under 5 years of age. In Tunisia, Kharfi, et al., described 106 cases of 
cutaneous leishmaniasis in children under 16 years of age, of which 6.8% 
also had mild mucosal lesions (19). In 2007, De Oliveira Guerra reported 147 
cases of American tegumentary leishmaniasis in children less than 15 years 
of age in Brazil, of which one had concomitant skin and mucosal lesions (20).
In Colombia, there are few studies on this clinical form of the disease. In 
1998, Osorio described a series of 23 patients with mucosal leishmaniasis 
caused by L. (V.) panamensis in the Pacific region of Colombia (6). The 
distribution by age and gender, as well as the most frequent location of the 
lesion, was similar to that of the patients included in this study. In contrast, in 
Osorio’s study, differences in the frequency of septal perforation (reported in 
15% of patients) and the presence of previous scarring indicative of cutaneous 
leishmaniasis (only reported in 17% of patients) were observed. The presence 
of simultaneous mucosal and cutaneous lesions was reported in 78% of patients 
but was observed only in 8% of the patients in this study. The time of evolution of 
the disease in that study ranged between 1 month and 10 years with an average 
of 23 months, which indicated an earlier diagnosis compared with our series. 
An important difference in the two study groups is the infecting species. 
Approximately 90% of the species in this series corresponded to L. (V.) 
braziliensis unlike Osorio’s series in which 77% of the species identified were 
L. (V.) panamensis. The difference in the severity of the lesions between the 
two studies could be explained by the differences in the infecting species or 
differences in the time until diagnosis.
It is pertinent to ask whether mucosal leishmaniasis patients in Colombia 
are being diagnosed in a timely manner, whether there are barriers to access 
the health system, and whether there is a lack of specific training in health 
professionals about this disease. It is fundamental to strengthen the education 
of general practitioners in this area to improve the diagnosis in our patients 
including an adequate mucosal evaluation and a more frequent follow-up in 
patients with cutaneous leishmaniasis caused mainly by L. (V) braziliensis.
We report the largest series of mucosal leishmaniasis patients in Colombia 
where the predominant species was L. (V.) braziliensis and one of the cases 
was caused by L. (L.) amazonensis. 
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